MedTrace Logo

Pregnancy Repository

NCT06339606 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 7000

Last updated 2024-04-24

No results posted yet for this study

Summary

An essential part of clinical research is the availability and accessibility of human biospecimens for the identification of biomarkers, new treatments and measurement of response to therapy. Proteins, RNA and DNA can be extracted and studied as well. This is a critical first step in performing many fundamental molecular biology experiments. A variety of biospecimens are utilized for research including but not limited to normal and malignant tissues, blood, and other body fluids.

In order to obtain high-quality biospecimens, they must be acquired serially, stored according to current standards, and matched with clinical information for maximum value. As such, the investigators would like to create a repository of biospecimens collected from pregnant patients who are seen at Mount Sinai Hospital and other research hospitals in Toronto. Mount Sinai provides personnel and infrastructure to serve the largest (7500 births/year) and highest complex Maternity program in Ontario. Of the 7500 patients a year, at least 2500 are considered high risk pregnancies, where there's a possibility of preeclampsia, placenta accreta and a host of other complications. For this study, biological specimens - blood, cervical and placental samples - will be collected from these high-risk groups in order to better understand the causes of the underlying conditions.

Conditions

  • Pregnancy Related
  • Fetal Growth Retardation
  • Placental Insufficiency
  • Preeclampsia
  • Cervix; Pregnancy

Interventions

OTHER

Biospecimen collection

Biospecimens, including maternal blood and cervical mucus will be collected serially during pregnancy. After delivery tissue samples from the placenta and umbilical cord blood will be collected.

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Sascha Drewlo, PhD · Sunnybrook Research Institute

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2026-04-30
Completion
2031-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06339606 on ClinicalTrials.gov